From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of motor neurons. Using unbiased transcript profiling in an ALS mouse model, we identified a role for the co-stimulatory pathway, a key regulator of immune responses. Furthermore, we observed that this pathway is upregulated in the blood of 56% of human patients with ALS. A therapy using a monoclonal antibody to CD40L was developed that slows weight loss, delays paralysis and extends survival in an ALS mouse model. This work demonstrates that unbiased transcript profiling can identify cellular pathways responsive to therapeutic intervention in a preclinical model of human disease.

[1]  A. Aruffo,et al.  CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. , 1996, Transplantation.

[2]  C. Cooper,et al.  Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer , 2007, Nature Clinical Practice Urology.

[3]  H. Paulson,et al.  SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. , 2008, The Journal of clinical investigation.

[4]  H. Hartung,et al.  Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. , 1998, Brain : a journal of neurology.

[5]  A. Aruffo,et al.  The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. , 1993, Journal of immunology.

[6]  R. Pope,et al.  Co-stimulatory pathways in the therapy of rheumatoid arthritis , 2009 .

[7]  I. Stamenkovic,et al.  A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Waldmann,et al.  CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. , 1999, Journal of immunology.

[9]  S. Appel,et al.  CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS , 2008, Proceedings of the National Academy of Sciences.

[10]  Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. , 2004 .

[11]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[12]  R. Hughes,et al.  Sural nerve biopsies in Guillain‐Barre syndrome: Axonal degeneration and macrophage‐associated demyelination and absence of cytomegalovirus genome , 1992, Muscle & nerve.

[13]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[15]  Benno Schwikowski,et al.  Discovering regulatory and signalling circuits in molecular interaction networks , 2002, ISMB.

[16]  S. Mckercher,et al.  Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis , 2006, Proceedings of the National Academy of Sciences.

[17]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[18]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[19]  A. Aruffo,et al.  CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Kalled,et al.  Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis , 2001, Lupus.

[21]  C. Janeway,et al.  Requirement for CD40 Ligand in Costimulation Induction, T Cell Activation, and Experimental Allergic Encephalomyelitis , 1996, Science.

[22]  P. Linsley,et al.  Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. , 1997, Journal of immunology.

[23]  D. Troost,et al.  Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis , 1990, Neuropathology and applied neurobiology.

[24]  C. Mohan,et al.  Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. , 1995, Journal of immunology.

[25]  A. Aruffo,et al.  Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.

[26]  R. Flavell,et al.  Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice , 2002, Nature Neuroscience.

[27]  B Alex Merrick,et al.  Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. , 2004, Current opinion in molecular therapeutics.

[28]  P. Mcgeer,et al.  Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. , 1992, The American journal of pathology.

[29]  S. Perrin,et al.  No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS , 2009, PloS one.

[30]  H. Waldmann,et al.  Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance1 , 2000, The Journal of Immunology.

[31]  D. Harlan,et al.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Aruffo,et al.  CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. , 1992, Immunology today.

[34]  P. Linsley,et al.  T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Burkly,et al.  FcR Interactions Do Not Play a Major Role in Inhibition of Experimental Autoimmune Encephalomyelitis by Anti-CD154 Monoclonal Antibodies , 2004, The Journal of Immunology.

[36]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[37]  D. Troost,et al.  Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. , 1989, Clinical neuropathology.

[38]  N. Schaeren-Wiemers,et al.  RNA profiling of MS brain tissues. , 2008, International MS journal.

[39]  J. Soria,et al.  Gene expression profiling of non-small-cell lung cancer , 2008, Expert review of molecular diagnostics.

[40]  J. Tajti,et al.  Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. , 1993, Archives of neurology.

[41]  E. Simpson,et al.  Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade , 2003, Nature Medicine.

[42]  M. Decristofaro,et al.  Toxicogenomics in biomarker discovery. , 2008, Methods in molecular biology.

[43]  H. Gendelman,et al.  Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice , 2008, PloS one.

[44]  R. Flavell,et al.  Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. , 1996, Journal of immunology.

[45]  J. Nevins,et al.  Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. , 2007, The Lancet. Oncology.